AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03755193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonates and ELD Edirol®Tablet 0.75ug
Description: To examine the effects of BP and ELD in osteoporosis patients
Study NCT03755193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ELD Edirol®Tablet 0.75ug
Description: To examine the effects of ELD in osteoporosis patients
Study NCT03563547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling (fat modifed diet)
Description: Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
Study NCT03563547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling (fat modified + soy enriched diet)
Description: Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target.
Study NCT02045602 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Genetically modified human adenovirus encoding human PH20 hyaluronidase
Study NCT02045602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous administration
Study NCT02045602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: 125 mg/m2 intravenous administration
Study NCT01493414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Study NCT03037970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhPDGF-BB
Description: One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
Study NCT03037970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen Wound Dressing wetted with buffer.
Study NCT04439266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT01648543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar sympathetic ganglion block
Study NCT01463046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Study NCT03895372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 or Placebo
Description: Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
Study NCT01463046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
Study NCT01463046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
Study NCT03773120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Neuromonitoring to find EBSLN
Description: intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
Study NCT03505619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST 1.0
Description: 10 weeks intervention applying a person-centred approach by using goal setting and smart products.
Study NCT04281745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CORETOX Inj
Description: Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
Study NCT02701855 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive tests
Description: Cognitive tests include:~* The MMSE (Mini Mental State Examination)~* Free and Cued Selective Recall Reminding Test (FCSRT).~* Executive functions (fluencies, TMT A and B, span).~* Tests of verbal fluency (literal and category)~* Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~* The Clinical Dementia Rating Scale~* The IADL scale evaluates autonomy.~* Geriatric Depression screening Scale (GDS)
Study NCT02701855 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
Study NCT03895372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647
Description: Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
Study NCT00750399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
Study NCT00750399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: intravitreal ranibizumab 0.5 mg
Study NCT00584857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel ,Carboplatin , Megesterol Acetate
Description: Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
Study NCT03525847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endosonography
Description: Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
Study NCT01646827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: One injection of 400 mg aripiprazole IM depot
Study NCT03628417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calcium Electroporation
Description: If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis.
Study NCT04626726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T infusion for patients with CD19 positive tumor cells
Study NCT04626726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: CD22 CAR-T infusion for patients with CD22 positive tumor cells
Study NCT02701855 — intervention group
Intervention type: RADIATION
Intervention: Brain and aorta RMI
Description: A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
Study NCT04626726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19+CD22 CAR-T
Description: CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
Study NCT04626726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2
Study NCT04626726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study NCT04552054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality+ 3D printing guided localization
Description: Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
Study NCT04552054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Tomography guided localization
Description: CT-guided percutaneous lung puncture staining marker localization.
Study NCT02588014 — intervention group
Intervention type: OTHER
Intervention: Magnetoencephalography
Description: Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
Study NCT01596270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT02701855 — intervention group
Intervention type: OTHER
Intervention: Adaptative optics
Description: The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging.
Study NCT03628417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bleomycin based electrochemotherapy
Description: If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis.
Study NCT02693483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% povidone iodine
Description: Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
Study NCT03089294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aries ED device
Description: The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
Study NCT03358082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.03% Ointment
Description: topical tacrolimus 0.03% twice daily for 6 months
Study NCT03358082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Acetate 1% Ointment
Description: hydrocortisone acetate 1% ointment twice daily for 6 months
Study NCT00114348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R-Blocks
Study NCT00114348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol II-Ida
Study NCT04635852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT04635852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release morphine
Study NCT03939390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: time of administration of Corifollitropin Alfa
Description: The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
Study NCT02783833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40mg
Study NCT02783833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 dose to be determined mg
Description: Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
Study NCT01276951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delivery and return of chocolate
Description: At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
Study NCT03301766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine 5% patch
Description: transdermal patch
Study NCT03301766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
Study NCT03301766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
Study NCT04304859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BASIC
Description: Validation
Study NCT02538263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume-targeted noninvasive ventilation
Study NCT02519699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine
Description: Increase in mean arterial pressure using norepinephrine
Study NCT02098382 — intervention group
Intervention type: DEVICE
Intervention: Dilapan-S
Description: Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
Study NCT03301766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-medicated patch
Description: non-medicated patch
Study NCT01386710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Carboplatin
Description: Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle
Study NCT01386710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Carboplatin
Description: Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle
Study NCT03132480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid resuscitation
Description: when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
Study NCT04217577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried plums
Description: 10-16 dried plums/day, approximately 100-120 g/day
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride 0.5 mg
Description: Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500mg/day for 05 days
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500mg/day for 05 days
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: 500mg twice daily for 06 days
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: 500mg twice daily for 06 days
Study NCT04729491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
Study NCT03011034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talacotuzumab
Description: Talacotuzumab 9 mg/kg will be administered as an IV infusion.
Study NCT03011034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg will be administered as an IV infusion.
Study NCT01188915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive screening
Description: Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
Study NCT01710111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Recipients Face Shield
Description: Face shield and repeat hand hygiene measures
Study NCT01389622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: National Acupuncture Detoxification Association (NADA) points + digital pressure
Study NCT01389622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: random points + digital pressure
Study NCT03196271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ketocal 2.5:1
Description: A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
Study NCT01513226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycled light
Description: lights on at daytime, lights off at nighttime
Study NCT01863407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAM
Description: composed of dexamethasone, allantoin and metronidazole
Study NCT01863407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline 250ml
Study NCT01540461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
Study NCT03122574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: 100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
Study NCT03122574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba Aromatherapy
Description: 100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
Study NCT03432910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate
Description: The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
Study NCT02134327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Dexmedetomidine with Midazolam
Study NCT00598195 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Ketamine
Description: subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.